Citius Pharmaceuticals, Inc. announced completion of the acquisition of Leonard-Meron Biosciences, Inc. Prior to the acquisition, Mr. Leonard Mazur was the Chief Executive Officer and Chairman of the Board of Directors of Citius and a principal stockholder of LMB; and, Mr. Myron Holubiak was the President and Chief Executive Officer of LMB, a significant stockholder of LMB, and a director of Citius. Pursuant to the acquisition, Mr. Holubiak assumed the role of President and Chief Executive Officer of Citius and will continue as a director of Citius, and Mr. Mazur will remain as the Chairman of the Board of Citius.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6825 USD | +4.10% | +3.41% | -9.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.78% | 123M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CTXR Stock
- News Citius Pharmaceuticals, Inc.
- Citius Pharmaceuticals, Inc. Announces Management Changes